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Objective: We aimed to determine in relapsing multiple sclerosis (MS) whether intrathecal synthesis of immunoglobulin
(Ig) M and IgG is associated with outcomes reflecting inflammatory activity and chronic worsening.
Methods: We compared cerebrospinal fluid analysis, clinical and magnetic resonance imaging data, and serum neu-
rofilament light chain (sNfL) levels at baseline and follow-up in 530 patients with relapsing MS. Patients were categorized
by the presence of oligoclonal IgG bands (OCGB) and intrathecal synthesis of IgG and IgM (intrathecal fraction [IF]: IgGIF
and IgMIF). Relationships with the time to first relapse, sNfL concentrations, T2-weighted (T2w) lesions, MS Severity Score
(MSSS), and time to initiation of high-efficacy therapy were analyzed in covariate-adjusted statistical models.
Results: By categorical analysis, in patients with IgMIF the median time to first relapse was 28 months shorter and MSSS
on average higher by 1.11 steps compared with patients without intrathecal immunoglobulin synthesis. Moreover,
patients with IgMIF had higher sNfL concentrations, more new/enlarging T2w lesions, and higher total T2w lesion
counts (all p ≤ 0.01). These associations were absent or equally smaller in patients who were positive for only OCGB or
OCGB/IgGIF. Furthermore, quantitative analyses revealed that in patients with IgMIF ≥ median, the time to first relapse
and to initiation of high-efficacy therapy was shorter by 32 and by 203 months, respectively (both p < 0.01), in compari-
son to patients with IgMIF < median. Dose-dependent associations were also found for IgMIF but not for IgGIF with
magnetic resonance imaging-defined disease activity and sNfL.
Interpretation: This large study supports the value of intrathecal IgM synthesis as an independent biomarker of disease
activity and severity in relapsing MS.
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The clinical course of multiple sclerosis is heterogeneousand unpredictable on individual grounds at the time
of diagnosis. Biomarkers bridging this prognostic gap are
urgently needed for personalized therapeutic decision
making. The presence of oligoclonal immunoglobulin
(Ig) G bands (OCGB) in cerebrospinal fluid (CSF) is a
diagnostic hallmark of multiple sclerosis and was recently
reintroduced in the early diagnostic algorithm for multiple
sclerosis to satisfy the criterion of dissemination in time.1
Besides this qualitative measure, intrathecal accumulation
of B cells and plasma cells can also be detected by intra-
thecal production of IgG (intrathecal fraction of IgG
[IgGIF]),
2 which has been found in 70 to 86%2,3 of
patients with multiple sclerosis. In a large clinically iso-
lated syndrome (CIS) cohort, OCGB and the presence of
intrathecal IgGIF were associated with 1.4- and 1.6-fold
increased4 likelihoods of conversion to multiple sclerosis.
Unlike the adaptive immune response in lymphatic tissue,
where the initial production of IgM is typically supplanted
by IgG owing to an isotype switch of B cells, intrathecal
production of IgM persists as a characteristic feature of
multiple sclerosis.5 The intrathecal fraction of IgM
(IgMIF) according to Reiber’s formula
2 is present in up to
23% of multiple sclerosis patients.4,6,7
The presence of OCMB has been reported to be
associated with a more active inflammatory disease pheno-
type, both in relapsing and in primary progressive multiple
sclerosis.8–11
Moreover, some studies have found that quantitated
intrathecal IgM synthesis is associated with a higher likeli-
hood of conversion from CIS to clinically definite multi-
ple sclerosis and a more severe disease course,4,7,12,13 but
other studies did not confirm this finding.6,14,15 Little is
known how intrathecal IgM and IgG synthesis are associ-
ated independently with magnetic resonance imaging
(MRI) and body fluid markers related to progression and,
eventually, the choice of therapy, and whether this relation
is dose-dependent.
The aim of this study was to investigate the added
value of quantitative estimates of IgMIF and IgGIF to
prognosticate the long-term disease activity and severity
based on the time interval between first symptoms and a
first relapse, the Multiple Sclerosis Severity Score (MSSS),
respectively, and the level of longitudinal development of
neuroaxonal damage and disease burden as measured by
serum neurofilament light chain (sNfL) and MRI lesions.
Lastly, we explored how these measures correlated with
the physician’s decision to initiate or to switch to high-
efficacy disease-modifying therapies (heDMT).
Patients and Methods
Patients
We included participants in the Swiss Multiple Sclerosis
Cohort Study (SMSC) diagnosed as either CIS or multiple
sclerosis,1,16,17 who had a lumbar puncture (LP) with com-
plete analysis of OCGB, IgGIF, IgMIF, and the intrathecal
fraction of IgA (IgAIF). The initial clinical event and first
relapse were defined as new, worsening (in the case of first
relapse), or recurrent neurologic symptoms that lasted for
≥24 hours without fever, infection, or adverse reaction to a
prescribed medication and that were preceded by a stable
or improving neurologic status of ≥30 days (in the case of
first relapse). Institutional review boards at the respective
SMSC centers approved the study, and written informed
consent was obtained from all participants.
Baseline and Follow-Up Clinical Data, Multiple
Sclerosis Data, and Serum Collection
Demographic and clinical variables collected at the base-
line visit included sex, date of birth, date of onset of
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multiple sclerosis symptoms, and first relapse (2 patients
experienced their first relapse with unknown date) where
applicable, and current and previous disease-modifying
therapies (DMTs). Therapies were categorized into
“heDMT” (ocrelizumab, rituximab, alemtuzumab, and
natalizumab), “oral” (teriflunomide, dimethyl fumarate,
fingolimod, and siponimod), “platform” (interferon beta
and glatiramer acetate), and “untreated”. Standardized
clinical assessments based on Expanded Disability Status
Scale (EDSS) scores were performed by certified raters
(http://www.neurostatus.net) at baseline and each follow-
up visit every 6 or 12 months.16,18 Blood samples were
collected within 8 days from the clinical visit and
processed and stored at 80C following standardized
procedures. The median (interquartile range [IQR])
follow-up from baseline was 5.1 (3.0–7.0) years.
Cerebrospinal Fluid Analysis
OCGBs were assessed by isoelectric focusing followed by
immunoblotting, immunofixation, or silver staining
(depending on the study center). Testing of OCGBs was
considered positive if pattern 2 or 3 (local synthesis of IgG
within the central nervous system) was present.19 CSF and
serum concentrations of IgA, IgG, IgM, and albumin were
measured nephelometrically. We used the derived CSF-to-
serum quotients for Igs and albumin (QIgG, QIgM, QIgA, and
Qalb) for calculations of the intrathecal Ig synthesis according
to the formulae proposed by Reiber and colleagues.2
The amount of intrathecal IgG, IgM, or IgA synthe-
sis was expressed as the intrathecal fraction as a percentage
of the total measured isotype concentration in CSF
(IgGIF, IgMIF, and IgAIF).
2 The integrity of the blood–
CSF barrier was determined by calculating the Qalb.
20
Serum Neurofilament Light Chain Measurements
sNfL was measured (at baseline and every 6 or
12 months) with the NF-light® assay (Quanterix, Biller-
ica, MA, USA).
Intra- and interassay variability were evaluated with
3 native serum samples in each of the runs on indepen-
dent days. The mean coefficients of variation (CVs) of
duplicate determinations for concentration were 5.5%
(6.2pg/ml, sample 1), 3.3% (18.9pg/ml, sample 2), and
3.1% (37.3pg/ml, sample 3). Interassay CVs were 7.0%
(sample 1), 5.6% (sample 2), and 5.6% (sample 3). For
the generation of age-dependent sNfL Z-scores, we used
sNfL measurements in 8,865 samples of 4,209 healthy
controls (median age = 44.8 years).21
Magnetic Resonance Imaging
Brain MRI scans were performed annually in 1.5
(n = 940) or 3T (n = 978) scanners. The imaging
protocol was standardized across centers and included a
3-dimensional magnetization prepared – rapid gradient
echo (MPRAGE) and a 3-dimensional fluid attenuated
inversion recovery (FLAIR) sequence, which were acquired
at a spatial resolution of 1mm.3 The number and occur-
rence of new/enlarging T2-weighted (T2w) lesions were
automatically assessed annually by using a deep learning-
based approach22 and a longitudinal evaluation method,23
respectively, followed by manual quality assessment and
correction.
Statistical Analysis
Data are presented as the median and interquartile range
(IQR) or mean and standard deviation (SD), and as abso-
lute and relative frequencies in the case of categorical data.
Categorical Analysis. Given that the presence of intrathe-
cal Ig subtypes is not distributed evenly and indepen-
dently, in a first step the patients were categorized in
ascending order for the presence or absence of OCGB,
IgGIF (>0% vs 0%) and IgMIF (>0% vs 0%; Fig 1):
(1) OCGB/IgGIF
/IgMIF
 (ie, absence of OCGB and




n = 114; (3) OCGB+/IgGIF
+/IgMIF
, n = 229; and (4)
OCGB+/IgGIF
+/IgMIF
+ (ie, presence of OCGB and
IgGIF and IgMIF), n = 111. Eleven of 530 patients
(2.1%) were IgGIF
+, IgMIF
+, or IgA IF
+ in combination
with OCGB, whereas 19 of 530 (3.6%) had an
OCGB+/IgGIF
/IgMIF
+ combination; all these were
excluded from this categorization.
In a second step, we investigated associations
between demographic (sex and age) or CSF parameters







; above categories 2–4 vs cate-
gory 1) with described endpoints (time to a first relapse,
longitudinal sNfL levels, MRI lesions, MSSS, and time to
heDMT) by univariable (Cox proportional hazards, linear
mixed, negative binominal mixed, and linear) models,
respectively.
Next, associations between these 4 categories and
time to first relapse and time to first initiation of an
heDMT were investigated by multivariable Cox propor-
tional hazards models, adjusted for age at first symptoms,
sex, and DMT category (heDMT, oral, platform, or
untreated; DMT category was a time-varying covariate).
To analyze associations between the CSF categories and
longitudinal sNfL concentrations, age-dependent sNfL Z-
scores were modeled in healthy controls using a general-
ized additive model for location, scale, and shape
(GAMLSS) to reflect the deviation of a patient’s sNfL
value from the mean value of same-age healthy controls.21
Serum NfL Z-scores (dependent variable) were analyzed
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by multivariable linear mixed models adjusted for sex and
DMT category at the respective visits for blood sampling.
T2w hyperintense lesion counts and the occurrence
of new/enlarging T2w hyperintense lesions were analyzed
by multivariable mixed negative binomial models includ-
ing disease duration or time between MRI scans, respec-
tively as offset, and adjusted for age at first symptoms, sex,
and dominant DMT category (DMT category with lon-
gest treatment duration) or DMT category at visit, respec-
tively. MSSS (calculated at the last follow-up visit) was
analyzed by a multivariable linear model, adjusted for age,
sex, and dominant treatment category.
Quantitative Analysis. In a fourth step, we investigated in
OCGB+/IgGIF
+/IgMIF
+ patients whether there was an
association between the outcomes above and the quantita-
tive amount of IgGIF/IgMIF by (1) splitting at median
IgGIF/IgMIF, and (2) including IgGIF and IgMIF as con-
tinuous variables in the same (ie, “combined”) model in
order to assess their potential individual and independent
contributions. For all endpoints, the same model structure
described above was used and adjusted for the same
covariables.
For time to first relapse and time to start of an
heDMT, IgMIF was additionally assessed by splitting at the
median in OCGB+/IgGIF
+/IgMIF
+, and IgGIF by splitting
at the median in OCGB+/IgGIF
+/IgMIF
 patients.
For each model, the estimated effect of the Ig
parameter is presented together with its 95% confidence
intervals (CIs) and p-value. In addition, the estimates
(marginal effects) are presented graphically by extracting
the predicted values together with their 95% CIs using
the R package sjPlot.24
Time to first relapse and time to first initiation of an
heDMT are presented in Kaplan–Meier curves.
Model assumptions were assessed using graphical
methods. For the Cox proportional hazard models, we
inspected Schoenfeld’s residuals. Linear models were assessed
by checking residuals and leverages. The residuals were
checked by visual inspection using a plot of the residuals ver-
sus the fitted values, in addition to a normal Q-Q plot. All
analyses were conducted using the statistical software
R (version 3.6.3) (R is an open-source, interpreted (statisti-
cal) programming language available at www.r-project.org).
Results
Demographic, Clinical, and CSF Characteristics
Five hundred and thirty patients were included in this
study (Table 1). OCGBs were detected in 473 (89.2%);
340 (71.9%) of those had IgGIF, 27.5% IgMIF, and
FIGURE 1: Combination of CSF immunoglobulin synthesis and frequencies in patients with and without presence of oligoclonal
IgG bands. OCGB were present (+) in 473 patients, and 340 of them had additional IgGIF and 130 showed presence of IgMIF,
whereas 46 had no () OCGB, IgGIF, and IgMIF. Patients were categorized into the following 4 groups according to the presence
or absence of OCGB, IgGIF, and IgMIF: (1) OCGB
/IgGIF
/IgMIF
, n = 46 (green); (2) OCGB+/IgGIF
/IgMIF
, n = 114 (light blue);
(3) OCGB+/IgGIF
+/IgMIF
, n = 229 (blue); and (4) OCGB+/IgGIF
+/IgMIF
+, n = 111 (red). The presence of IgMIF coincided with
that of IgGIF in 85.4% (111 of 130) samples (only 19 of 130 patients [15.6%] had an OCGB
+/IgGIF
/IgMIF
+ pattern). In OCGB,
11 of 530 patients (2.1%) showed IgGIF
+, IgMIF
+, or IgAIF
+ and were excluded from this categorization (not shown in figure).
CSF = cerebrospinal fluid; IgG = immunoglobulin G; IgGIF/MIF/AIF = immunoglobulin G/M/A intrathecal fraction; IgM =
immunoglobulin M; OCGB = oligoclonal IgG bands; + = presence of OCGB or IgG/IgM by Reiber formula;  = absence of OCGB
or IgG/IgM by Reiber formula.
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12.3% IgAIF (65.1, 26.0, and 11.7%, respectively, of the
entire cohort; see Fig 1).
At the time of LP, 319 (60.2%) patients had experi-
enced 1 clinical attack and 211 (39.8%) ≥2 clinical attacks
(see Table 1). CSF variables between patients with LP
before versus after first relapse were similar (Table S1).
The following results were based on multivariable
analyses; all corresponding univariable analyses showed
congruent results (Table S2).
Time Interval between First Symptoms and First
Relapse. Three hundred and ninety-two (74.0%) patients
had a first relapse (second clinical attack), whereas
138 (26.0%) patients remained relapse free during a




+ patients had a 94% higher
risk of experiencing a first relapse (hazard ratio [HR] 1.94
[CI: 1.24, 3.05], p < 0.01) compared with patients with-
out intrathecally produced Ig (OCGB/IgGIF
/IgMIF
).
In contrast, the IgGIF status was not associated with time




(Table 2A). Accordingly, the median time to first relapse



















n (%) 530 (100) 46 (8.7) 114 (21.5) 229 (43.2) 111 (20.9)
Female, n (%) 355 (67.0) 31 (67.4) 56 (49.1) 169 (73.8) 78 (70.3)
Age at first symptoms,
mean (SD), yr
33.5 (10.7) 36.0 (11.8) 35.3 (11.3) 33.4 (10.0) 31.0 (10.9)
Characteristics at LP
1 clinical event, n (%) 319 (60.2) 34 (73.9) 69 (60.5) 133 (58.1) 65 (58.6)
≥2 clinical events, n
(%)
211 (39.8) 12 (26.1) 45 (39.5) 96 (41.9) 46 (41.4)
Age, mean (SD), yr 35.7 (11.0) 38.3 (13.8) 37.8 (11.5) 35.9 (10.0) 32.7 (11.1)
First symptoms to LP,
median (IQR), mo
2.8 (0.4, 20.7) 1.5 (0.3, 10.5) 3.9 (0.4, 18.0) 3.1 (0.4, 25.4) 2.0 (0.3, 19.8)
DMT before LP 18 (3.4) 3 (6.5) 3 (2.6) 10 (4.4) 2 (1.8)
HeDMT before LP 4 (0.7) 1 (2.2) 0 (0) 2 (0.9) 0 (0)
CSF characteristics
OCGB+, n (%) 473 (89.2) 0 (0) 114 (100) 229 (100) 111 (100)
IgGIF
+, n (%) 345 (65.1) 0 (0) 0 (0) 229 (100) 111 (100)
IgMIF
+, n (%) 138 (26.0) 0 (0) 0 (0) 0 (0) 111 (100)
IgAIF
+ (n, %) 62 (11.7) 0 (0) 7 (6.1) 25 (10.9) 22 (19.8)
Albumin quotient,
median (IQR)
4.9 (3.9, 6.5) 5.1 (4.4, 6.7) 6.0 (4.6, 8.3) 5.0 (3.9, 6.4) 4.2 (3.4, 5.0)
White cell count,
median (IQR), n/μl
5.0 (2.3, 10.3) 2.0 (1.0, 4.0) 4.0 (2.0, 6.7) 5.6 (3.0, 10.7) 10.0 (5.0, 19.0)
aEleven of 530 patients were OCGB and IgGIF
+ and/or IgMIF
+ and/or IgAIF
+, and 19 of 530 patients had an OCGB+/IgGIF
/IgMIF
+ pattern;










CSF = cerebrospinal fluid; heDMT = high-efficacy disease-modifying treatment; IgG/M/AIF = immunoglobulin G/M/A intrathecal fraction;
IQR = interquartile range; LP = lumbar puncture; OCGB = oligoclonal IgG bands.
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(median time to first relapse 18 vs 36 vs 30 months,




TABLE 2. Multivariable Models for the Following
Outcomes: (A) Time to First Relapse, (B) sNfL
Z-scores, (C) sNfL Z-scores in Untreated Patients,
(D) Total T2w Lesion Count, (E) New/Enlarging T2w
Lesion Count, (F) Multiple Sclerosis Severity Score
and (G) Time to First Initiation of a heDM
A. Time to First Relapse n HR CI p
Male versus female 498 0.93 0.74, 1.17 0.528
Age 498 0.99 0.98, 1.00 0.237
OCGB+/IgGIF
/IgMIF
a 114 1.45 0.93, 2.27 0.102
OCGB+/IgGIF
+/IgMIF
a 228 1.40 0.92, 2.14 0.115
OCGB+/IgGIF
+/IgMIF
+a 110 1.94 1.24, 3.05 <0.01
B. sNfL Z-scores n Est. CI p
Male versus
female















716 0.41 0.04, 0.78 0.032
C. sNfL Z-scores in
Untreated Patients n Est. CI p















88 1.18 0.53, 1.83 <0.01
D. T2w Lesion
Count n IRR CI p
Male versus
female
1795 1.16 0.91, 1.48 0.226















414 2.53 1.63, 3.93 <0.01
E. New/Enlarging
T2w Lesion Count n IRR CI p
Male versus female 838 0.93 0.55, 1.58 0.789















195 3.13 1.29, 7.58 0.011
F. Multiple
Sclerosis Severity
Score n Est. CI p
Male versus female 499 0.70 0.30, 1.10 <0.01















111 1.11 0.38, 1.84 <0.01
G. Time to First
Initiation of an
heDMT n HR CI p
Male versus female 500 1.06 0.79, 1.42 0.715















111 2.95 1.44, 6.02 <0.01
aComparator group: OCGB/IgGIF
/IgMIF
: n = 46 patients.
CI = 95% confidence interval; heDMT = high-efficacy disease-mod-
ifying treatment; HR = hazard ratio; IgGIF/MIF = immunoglobulin
G/M intrathecal fraction; OCGB+ = presence of oligoclonal IgG
bands.
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In the quantitative analysis, patients with IgMIF
levels above the median had their first relapse earlier than
those with values below the median (HR 1.86 [CI 1.18,
2.93], p < 0.01, n = 110; see Fig 2B), whereas the quan-
tity of IgGIF in OCGB
+/IgGIF
+/IgMIF
 patients was not
related to the time to the first relapse (HR 1.12 [CI 0.82,
1.52], p = 0.492, n = 228; see Fig 2C). In the model
combining IgMIF and IgGIF, patients with IgMIF above
versus below the median showed an increased hazard of a
first relapse, which was not seen for IgGIF (Table 3A).
Serum Neurofilament Light Chain Concentrations. sNfL
was measured in 520 patients with 3,260 longitudinal




+ patients had higher sNfL
Z-scores when compared with patients without intrathecal
Ig synthesis (OCGB/IgGIF
/IgMIF
; estimate 0.41 [CI
0.04, 0.78], p = 0.032; ie, OCGB+/IgGIF
+/IgMIF
+
patients had on average 0.41 standard deviations higher
sNfL concentrations). In those patients with presence of
only OCGB+ or OCGB+/IgGIF
+, sNfL Z-scores were
not elevated (Fig 3A; Table 2B).
In the combined model, sNfL Z-scores were higher
in patients with IgMIF above versus below the median,
whereas for IgGIF this was not the case. Similar results
were seen when using IgMIF and IgGIF as continuous vari-
ables (Table 3B).
In untreated patients (494 samples in 197 patients),
similar results were seen. The highest sNfL Z-scores were
found in OCGB+/IgGIF
+/IgMIF
+ patients (estimate 1.18
[CI 0.53, 1.83], p < 0.01), followed by only OCGB+ or
OCGB+/IgGIF
+ patients (see Fig 3B; Table 2C).
Again, in the combined model the patients with
IgMIF above versus below the median or with higher
IgMIF when analyzed as a continuous variable had
higher sNfL Z-scores, which was not seen for IgGIF
(Table 3C).
MRI: Total and New/Enlarging T2w Lesions. T2w lesion
count data were available from 488 patients and 1,918
MRIs (number of MRIs per patient: 4 [2–5]).
OCGB+/IgGIF
+/IgMIF
+ patients had on average
2.5 times more T2w lesions compared with patients with-
out intrathecal Ig (incidence rate ratio [IRR] 2.53
[CI 1.63, 3.93], p < 0.01, Table 2D; see Fig 3C). In the
combined model, we found numerically stronger effects
for IgM than for IgG (Table 3D).
Information on new/enlarging T2w lesions from
annual scans was available from 305 patients and 905
MRIs. OCGB+/IgGIF
+/IgMIF
+ patients had the highest
number of new/enlarging T2w lesions (IRR 3.13 [CI
1.29, 7.58], p = 0.011), with no such associations seen in
OCGB+ only and in OCGB+/IgGIF
+ patients (Table
2E; see Fig 3D).
Patients with IgMIF above versus below the median
or analyzed as a continuous variable had a higher inci-
dence of new/enlarging T2w lesions when analyzed in the
same model with IgGIF (Table 3E). A similar effect was
not seen for IgGIF (see Table 3E).
Disability (Multiple Sclerosis Severity Score). The MSSS
was on average higher by 1.11 points in OCGB+/IgGIF
+/
IgMIF
+ patients (estimate 1.11 [CI 0.38, 1.84], p < 0.01),
followed by those with OCGB+/IgGIF
+/IgMIF
 (estimate
0.86 [CI 0.19, 1.52], p = 0.012) and OCGB+/IgGIF
/
IgMIF
 (estimate 0.73 [CI 0.01, 1.45], p = 0.047), when
compared with those without intrathecal Ig synthesis
(Table 2F; see Fig 3E). No dose-dependent effects of IgMIF
+
(nor of IgGIF
+) were found in relation to MSSS (Table 3F).
Initiation of High-Efficacy Disease-Modifying Treatments
HeDMT was started in 223 of 530 patients (42.1%; no previ-
ous DMT: 66 [29.6%]; escalation from platform therapies:
81 [36.3%]; escalation from oral treatments: 76 [34.1%]).
OCGB+/IgGIF
+/IgMIF
+ patients featured the highest proba-
bility of escalation to heDMT (HR 2.95 [CI 1.44, 6.02],
FIGURE 2: Kaplan–Meier analyses for probability of a first relapse (A–C) and escalation to a high efficacy treatment (D–F).
(A) Median time to first relapse was shorter in OCBG+/IgGIF
+/IgMIF
+ (red line) than in OCGB/IgGIF
/IgMIF
 patients (green line;
18 vs 46 months, HR 1.94 [CI 1.24, 3.05], p < 0.01). Time to first relapse in OCGB+/IgMIF
 patients was not impacted by the
IgGIF status (light blue line = OCGB
+/IgGIF
/IgMIF
, median time 30 months; dark blue line = OCGB+/IgGIF
+/IgMIF
,
36 months). (B) In OCGB+/IgGIF
+/IgMIF
+ patients (n = 110), we saw a dose effect of the amount of IgMIF: patients with higher
IgMIF experienced a first relapse earlier than those with lower IgMIF (above [red line] vs below [orange line] median IgMIF: HR
1.86 [CI 1.18, 2.93], p < 0.01, n = 110). (C) For OCGB+/IgGIF
+/IgMIF
 patients, no such dose effect for IgGIF was found (HR 1.12
[CI 0.82, 1.52]; p = 0.492, n = 228). (D) Time to switch to heDMT was shortest in the OCGB+/IgGIF
+/IgMIF
+ group (red line;
median 105 months, HR 2.95 [CI 1.44, 6.02], p < 0.01; n = 111) versus OCGB/IgGIF
/IgMIF
 (green line), whereas in OCGB+/
IgGIF
/IgMIF
 (light blue line) it was 230 months, and in OCGB+/IgGIF
+/IgMIF
 (dark blue line) it was 206 months. (E) Patients
with increasing IgMIF levels showed an increased hazard for escalation to heDMT (above [red line] vs below [orange line] median
IgMIF: HR 2.28 [CI 1.30, 3.99]; p < 0.01; n = 111). (F) No increased hazard of switching to an heDMT was found for IgGIF
+ (above
[dark blue line] vs below [light blue line] median: HR 1.38 [CI 0.92, 2.09]; p = 0.124; n = 229). CI = 95% confidence interval;
heDMT = high-efficacy disease-modifying treatment; HR = hazard ratio; IgGIF/MIF = immunoglobulin G/M intrathecal fraction;
OCGB = oligoclonal IgG bands; + = presence of OCGB or IgGIF/IgMIF;
 = absence of OCGB or IgGIF/IgMIF.
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p < 0.01) compared with patients without intrathecal Ig synthe-
sis. In those with either only OCGB+ or OCGB+/IgGIF
+,
these effects were weaker (Table 2G). Accordingly, the time to
initiation of heDMT was shortest in the OCGB+/IgGIF
+/
IgMIF
+ (105 months) versus OCGB/IgGIF
/IgMIF

patients (given that only 26.8% were treated with heDMT
in this group, the median time to switch could not be





 patients it was 230 and
206 months, respectively (see Fig 2D); similar to the
analysis of the time interval to first relapse, the time to
heDMT in OCGB+/IgMIF
 patients was not impacted
by the IgGIF status. Again, this association was dose-





+ levels above the median
were associated with a >2-fold increased hazard for esca-
lation to heDMT (HR 2.28 [CI 1.30, 3.99], p < 0.01,
n = 111) versus those below the median (see Fig 2E),
whereas this was not the case for IgGIF
+ in patients with
only OCGB+/IgGIF
+ (HR 1.38 [CI 0.92, 2.09],
p = 0.12, n = 229; see Fig 2F). In the combined model,
similar results were found (Table 3G).
TABLE 3. Multivariable Models for Dose-dependent




Patients for the Following Outcomes: (A) Time to
First Relapse, (B) sNfL Z-scores, (C) sNfL Z-scores in
Untreated Patients, (D) Total T2w Lesion Count, (E)
New/Enlarging T2w lesion count, (F) Multiple
Sclerosis Severity Score and (G) Time to First
Initiation of a heDMT
A. Time to First Relapse HR CI p
1. IgMIF (> vs <median) 1.85 1.17, 2.92 <0.01
2. IgGIF (> vs <median) 1.13 0.73,1.75 0.578
3. IgMIF (per 1%) 1.01 1.00,1.02 0.064
4. IgGIF (per 1%) 1.01 1.00,1.02 0.180
B. sNfL Z-scores (n= 716) Est. CI p
1. IgMIF (> vs <median) 0.43 0.10,0.77 0.013
2. IgGIF (> vs <median) 0.01 0.32, 0.34 0.951
3. IgMIF (per 1%) 0.01 0.00, 0.02 0.034
4. IgGIF (per 1%) 0.00 0.01, 0.01 0.909
C. sNfL Z-scores in
untreated
patients (n = 88) Est. CI p
1. IgMIF (> vs <median) 0.92 0.18, 1.66 0.019
2. IgGIF (> vs <median) 0.15 0.88, 0.59 0.696
3. IgMIF (per 1%) 0.02 0.00, 0.04 0.032
4. IgGIF (per 1%) 0.00 0.02, 0.02 0.855
D. T2w Lesion
Count (n = 414) HR CI p
1. IgMIF (> vs <median) 1.63 0.96, 2.75 0.071
2. IgGIF (> vs <median) 1.02 0.61, 1.72 0.940
3. IgMIF (per 1%) 1.01 1.00, 1.02 0.271
4. IgGIF (per 1%) 1.01 0.99, 1.02 0.385
E. New/Enlarging T2w
Lesion
Count (n = 195) HR CI p
1. IgMIF (> vs <median) 2.86 1.25, 6.54 0.013
2. IgGIF (> vs <median) 1.04 0.49, 2.20 0.913
3. IgMIF (per 1%) 1.02 1.01, 1.02 <0.01
4. IgGIF (per 1%) 1.00 1.00, 1.01 0.417
F. Multiple Sclerosis
Severity
Score (n = 111) HR CI p
1. IgMIF (> vs <median) 0.59 0.23, 1.40 0.156
2. IgGIF (> vs
<median)
0.08 0.87, 0.71 0.843
3. IgMIF (per 1%) 0.01 0.01, 0.03 0.201
4. IgGIF (per 1%) 0.00 0.01, 0.02 0.680
G. Time to First
Initiation of an
heDMT (n = 111) HR CI p
1. IgMIF (> vs <median) 2.35 1.33, 4.16 <0.01
2. IgGIF (> vs <median) 0.87 0.51, 1.48 0.603
3. IgMIF (per 1%) 1.02 1.01, 1.03 <0.01
4. IgGIF (per 1%) 1.000 0.99, 1.01 0.944
Lines 1 and 2: Model 1: IgMIF and IgGIF split by median. Lines 3
and 4: Model 2: IgMIF and IgGIF as continuous variables.
CI = 95% confidence interval; heDMT = high-efficacy disease-
modifying treatment; HR = hazard ratio; IgGIF/MIF = immunoglob-
ulin G/M intrathecal fraction; OCGB+ = presence of oligoclonal
IgG bands.
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Discussion
The prediction of the individual course of multiple sclerosis
based on current clinical and MRI measures provides limited
accuracy for therapeutic decision making. OCGB are present
in up to 98% of multiple sclerosis patients and have been
reinstated as a diagnostic criterion in the 2017 MS diagnostic
criteria.1 However, the presence of OCGB as a prognostic
biomarker is relevant only in the minority of multiple sclero-
sis patients where they are absent, because this might go
along with a milder disease course.25
(Figure legend continues on next page.)
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OCMB have shown prognostic value,9,11,26–28 but
owing to the difficulties in standardizing the methodology,
this measure is not widely used. In contrast, the quantita-
tion of intrathecal Ig synthesis using the Reiber formulae
is a fully standardized analytical method.
Here, we have identified that the presence and, fur-
thermore, the quantity of IgMIF is a stronger and more
independent prognostic biomarker than OCGB and IgGIF
for acute disease activity (time interval from disease onset
to first relapse) and the chronic course of disability
(MSSS), and for biological and radiological measures
(sNfL Z-scores and MRI activity).
Additionally, we demonstrate that the presence of
intrathecal IgM production is associated with a first
choice of heDMT or an earlier switch to heDMT, as
the physician’s consequence for the need for a more
aggressive therapy. Moreover, this association holds
true also when the quantity of IgMIF, is considered; in
this case, we observed that the quantity of IgMIF is
related to a shorter time to DMT escalation and to
“time to first relapse,” in addition to increased sNfL
concentrations and disease activity as determined by
MRI measures. In contrast, the presence of IgGIF, or
the quantity of IgGIF in addition to OCGB has not
shown significant additional prognostic value (see
Tables 2 and 3; Figs 2 and 3). In line with prior
results,6 intrathecal IgAIF was relatively rare in the pre-
sent study cohort (present in 62 [11.7%] of patients;
see Table 1) and was not associated with any of the
outcomes (see Table S2), suggesting that its presence
might lack a relevant pathogenic role in multiple
sclerosis.
Our results are somewhat discordant with recent
data from the German multiple sclerosis cohort, in which
IgGIF but not IgMIF was associated with risk and shorter
time to EDSS worsening within 4 years.6 A potential
explanation for this discrepancy might be the different sta-
tistical approaches: unconfirmed EDSS worsening was
analyzed for individual Ig isotypes, whereas we adjusted
for the presence of OCGB, IgGIF, and IgMIF in combined
models. Furthermore, a longer observation time (median
9.0 vs 4 years since disease onset), a larger patient cohort
with disease worsening data (530 vs 330 patients) in
conjunction with different statistical approaches (no impu-
tation of data vs imputation of 27–41% of EDSS data at
year 4, additionally shortening observation interval) in our
study versus the German multiple sclerosis cohort study
might be additional factors.6
The contribution of antibodies and their capacity to
activate complement during the initial development of a
multiple sclerosis plaque has been demonstrated in
autopsy studies. Complement C3b colocalizes with IgG
and IgM deposits on oligodendrocytes and axons, leading
to demyelination and axonal injury.29,30 Intrathecal syn-
thesis of IgM (but not IgG or IgA) was shown to be asso-
ciated with early activation of the complement cascade,
with intrathecal activation of complement component C3,
which is in line with IgM being the most efficient isotype
for complement activation.31
An indication of a pathogenic role of intrathecal Ig
synthesis could be its longitudinal decrease under some
heDMTs in parallel to clinical improvement or stabilization
of disease. Continuous treatment with the B cell-targeting
drugs rituximab and ocrelizumab can lead to
FIGURE 3: Estimates (marginal effects) as derived from the multivariable analyses for serum neurofilament light chain Z-scores (A,
all patients; B, untreated patients), MRI disease activity (C, number of T2w hyperintense lesions; D, number of new/enlarging
lesions) and Multiple Sclerosis Severity Score (E) stratified by CSF immunoglobulin profiles. (A) sNfL Z-scores in all patients
(n = 491 with 3,045 longitudinal samples). After adjustment for covariates, OCGB+/IgGIF
+/IgMIF
+ patients had higher sNfL Z-
scores when compared with patients without any intrathecal Ig synthesis (Est. 0.41 [CI 0.04; 0.78], p = 0.032). In patients with
presence of only OCGB+ or OCGB+/IgGIF
+, sNfL Z-scores were not significantly elevated (Est. 0.10 [CI 0.27, 0.47], p = 0.594
and Est. 0.12 [CI 0.22, 0.46], p = 0.502). (B) sNfL Z-scores in untreated patients (n = 186 with 456 longitudinal samples). The
highest sNfL Z-scores were found in OCGB+/IgGIF
+/IgMIF
+ patients (Est. 1.18 [CI 0.53, 1.83], p < 0.01), and weaker effects on a
similar level for those patients with only OCGB+ or OCGB+/IgGIF
+ (Est. 0.71 [CI 0.06, 1.36], p = 0.033 and Est. 0.79 [CI 0.21,
1.38], p < 0.01) were found. (C) Total T2w lesion count (n = 458 patients with 1,795 longitudinal MRIs). OCGB+/IgGIF
+/IgMIF
+
patients had the highest T2 lesion counts (IRR = 2.53 [CI 1.63, 3.93], p < 0.01). Patients with only OCGB+ or OCGB+/IgGIF
+
showed smaller but similar effect sizes (IRR = 1.66 [CI 1.08, 2.57], p = 0.021 and IRR = 1.59 [CI 1.06, 2.37], p = 0.023,
respectively). (D) New/enlarging T2w lesion count (n = 282 patients with 838 longitudinal MRIs). OCGB+/IgGIF
+/IgMIF
+ patients
had the highest counts of new/enlarging T2 lesions (IRR = 3.13 [CI 1.29, 7.58], p = 0.011), with no effects in the other
2 categories (OCGB+ and OCGB+/IgGIF
+: IRR = 1.84 [CI 0.73, 4.62], p = 0.195 and IRR = 1.61 [CI 0.70, 3.69], p = 0.258,
respectively). (E) Multiple Sclerosis Severity Score (MSSS) (n = 499 patients). The MSSS was on average 1.11 points [CI 0.382,
1.843] higher in OCGB+/IgGIF
+/IgMIF
+ patients (Est. 1.112 [CI 0.382, 1.843], p < 0.01), followed by those with OCGB+/IgGIF
+/
IgMIF
 (Est. 0.855 [CI 0.190, 1.520], p = 0.012) and OCGB+/IgGIF
/IgMIF
 (Est 0.727 [CI 0.009, 1.445], p = 0.047), compared
with those patients without intrathecal immunoglobulin synthesis. Plots show the estimates (marginal effects) and median
together with their 95% CI. CI = 95% confidence interval; CSF = cerebrospinal fluid; MRI = magnetic resonance imaging;
Est. = estimate; IgGIF/MIF = immunoglobulin G/M intrathecal fraction; IRR = incidence rate ratio; OCGB = oligoclonal IgG bands;
sNfL Z-score = serum neurofilament light chain Z-score; T2w = T2-weighted; + = presence of OCGB or IgGIF/IgMIF;
 = absence
of OCGB or IgGIF/IgMIF.
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hypogammaglobulinemia,32–34 an effect that is more prom-
inent and occurs faster for IgM than for IgG. Only small
case series describe the course of intrathecal Ig synthesis
under rituximab or natalizumab therapy in multiple sclero-
sis: IgGIF decreased transiently under rituximab and ret-
urned to levels prior to therapy during months 6 to 9.35
Accordingly, intrathecal IgG synthesis (OCGB36,37; IgGIF
[Reiber formula]38) under natalizumab therapy decreased in
some patients, but returned after treatment cessation to ini-
tial levels.37 In contrast, intrathecal IgM synthesis and its
relation to treatment effects have not been evaluated; an
aspect we are now actively evaluating.
Limitations
Given that most patients entered the SMSC after the lum-
bar puncture had been performed, a correlation of intra-
thecal Ig synthesis with complete longitudinal EDSS
scores from disease start was not possible in our study. In
addition, our results are restricted mainly to CSF analysis
in an early phase of multiple sclerosis; an extension of the
CSF profiling into later stages of relapsing multiple sclero-
sis to gain a better understanding of the role of intrathecal
IgM synthesis and its value as biomarker is warranted.
Conclusions
Our study strongly supports the value of a quantitative
analysis of IgM levels in CSF as a prognostic biomarker,
independent of other Ig measures, which might be useful
for therapeutic decision making in the early phases of
disease.
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